Beruflich Dokumente
Kultur Dokumente
Dynamic cellular entry and release of Lawsonia intracellularis from infected ileum intestinal lining
Lawsonia - positive pigs are busy spreading the disease via their infected faeces.
As a result, the negative impact of ileitis tends to peak in finisher pigs.
These prevalence figures indicate that ileitis is not going away. In fact, in many countries, an increase has been observed. This increase may be due to tighter restrictions on the routine use of antibiotics.
Figure 2 (left) illustrates the progress of a typical ileitis attack in Asian and European farms. In the USA, the rise in ileitis infection typically occurs after the nursery stage has been completed. On Spanish farms, where the situation illustrated in figure 2 is the norm, Denagard premix formula has been used at 9 to 12 weeks of age to successfully reduce the clinical and sub-clinical signs of ileitis and improve overall pig performance.3 This better knowledge of suitable medications and when to give them has definitely had a positive impact on pig production by reducing the overall levels of ileitis infection.
This report was prepared in conjunction with Professor Steven McOrist, BVSc, PhD, MACVSc, DipECPHM
Nursery
su
ckl
ing
1s
tw
eek
2n
dw
eek
4th
we
ek
6th
we
ek
8th
we
ek 1
0th
we
ek
th 12
we
ek
th 14
we
ek
th 16
we
ek
References: 1. McOrist S, Barcellos DE, Wilson RJ. 2003. Global patterns of porcine proliferative enteropathy. Pig Journal 51, 26-35. (Updated data on file). 2. Wattanaphansak S, Singer RS, Gebhart CJ. 2009. In vitro antimicrobial activities against 10 North American and European Lawsonia intracellularis isolates. Veterinary Microbiology 134, 305-310 3. Cefusa Farm Veterinary Group (data on file). Novartis Animal Health Inc., PO Box CH-4002, Basel, Switzerland. Tel: +41 61 697 73 88 Fax: +41 61 697 67 88 www.denagard.com Denagard is a registered trademark of Novartis AG, Basel, Switzerland. Label indications, dosage rates and withdrawal periods may vary by country. Please refer to label in your country for approved usage instructions. 2009 Novartis Animal Health Inc. 200900086-1